Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
BIOD's Cash to Debt is ranked higher than
90% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. BIOD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
BIOD' s Cash to Debt Range Over the Past 10 Years
Min: 34.94  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
BIOD's Interest Coverage is ranked higher than
85% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIOD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
BIOD' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -7.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -43.44
BIOD's ROE (%) is ranked lower than
57% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. BIOD: -43.44 )
Ranked among companies with meaningful ROE (%) only.
BIOD' s ROE (%) Range Over the Past 10 Years
Min: -102.66  Med: -60.46 Max: -34.65
Current: -43.44
-102.66
-34.65
ROA (%) -40.56
BIOD's ROA (%) is ranked lower than
62% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. BIOD: -40.56 )
Ranked among companies with meaningful ROA (%) only.
BIOD' s ROA (%) Range Over the Past 10 Years
Min: -83.02  Med: -49.19 Max: -28.58
Current: -40.56
-83.02
-28.58
ROC (Joel Greenblatt) (%) -6649.58
BIOD's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. BIOD: -6649.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6649.58  Med: -1342.16 Max: -401.87
Current: -6649.58
-6649.58
-401.87
EBITDA Growth (3Y)(%) -36.20
BIOD's EBITDA Growth (3Y)(%) is ranked lower than
87% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. BIOD: -36.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIOD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.1  Med: -23.55 Max: 51.5
Current: -36.2
-47.1
51.5
EPS Growth (3Y)(%) -37.80
BIOD's EPS Growth (3Y)(%) is ranked lower than
85% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. BIOD: -37.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIOD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44  Med: -28.7 Max: 44.7
Current: -37.8
-44
44.7
» BIOD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-13)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BIOD Guru Trades in Q3 2015

Jim Simons 572,200 sh (-5.87%)
» More
Q4 2015

BIOD Guru Trades in Q4 2015

Jim Simons 2,944,505 sh (+414.59%)
» More
Q1 2016

BIOD Guru Trades in Q1 2016

Jim Simons 3,395,100 sh (+15.30%)
» More
Q2 2016

BIOD Guru Trades in Q2 2016

Jim Simons 3,569,471 sh (+5.14%)
» More
» Details

Insider Trades

Latest Guru Trades with BIOD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:ARNI, OTCPK:IMUN, OTCPK:ENDV, NAS:BLPH, NAS:TKAI, NAS:VKTX, NAS:WINT, NAS:CBLI, OTCPK:ANTB, NAS:ORPN, NAS:VTGN, AMEX:BPMX, NAS:CYAN, NAS:CSBR, NAS:MBVX, OTCBB:DDRT, NAS:ABIO, OTCPK:FENCF, NAS:CYCC, OTCPK:CSBTF » details
Traded in other countries:BDQN.Germany,
Biodel Inc is a specialty biopharmaceutical company. The Company is focused on the development and commercialization of treatments for diabetes patients.

Biodel Inc was incorporated in the State of Delaware on December 3, 2003 and commenced operations in January 2004. The Company is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that might be safer, more effective and more convenient for patients. The Company develops its product candidates by applying proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. Its most advanced program involves developing proprietary formulations of injectable recombinant human insulin, or RHI, designed to be more rapid-acting than the 'rapid-acting' mealtime insulin analogs currently used to treat patients with Type 1 and Type 2 diabetes. In addition to its ultra-rapid-acting insulin formulation program, the Company is developing a liquid glucagon formulation for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products.

Ratios

vs
industry
vs
history
P/B 0.97
BIOD's P/B is ranked higher than
94% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. BIOD: 0.97 )
Ranked among companies with meaningful P/B only.
BIOD' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.3
Current: 0.97
0
3.3
EV-to-EBIT 0.28
BIOD's EV-to-EBIT is ranked higher than
94% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. BIOD: 0.28 )
Ranked among companies with meaningful EV-to-EBIT only.
BIOD' s EV-to-EBIT Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.28
Current: 0.28
0
1.28
EV-to-EBITDA 0.28
BIOD's EV-to-EBITDA is ranked higher than
95% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. BIOD: 0.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIOD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.3
Current: 0.28
0
1.3
Current Ratio 11.31
BIOD's Current Ratio is ranked higher than
80% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. BIOD: 11.31 )
Ranked among companies with meaningful Current Ratio only.
BIOD' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 11.82 Max: 26.5
Current: 11.31
0.82
26.5
Quick Ratio 11.31
BIOD's Quick Ratio is ranked higher than
80% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. BIOD: 11.31 )
Ranked among companies with meaningful Quick Ratio only.
BIOD' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 11.82 Max: 26.5
Current: 11.31
0.82
26.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -63.70
BIOD's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. BIOD: -63.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIOD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -64.5  Med: -38 Max: -9.4
Current: -63.7
-64.5
-9.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.98
BIOD's Price/Net Cash is ranked higher than
97% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. BIOD: 0.98 )
Ranked among companies with meaningful Price/Net Cash only.
BIOD' s Price/Net Cash Range Over the Past 10 Years
Min: 0.61  Med: 1.96 Max: 7.18
Current: 0.98
0.61
7.18
Price/Net Current Asset Value 0.95
BIOD's Price/Net Current Asset Value is ranked higher than
98% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. BIOD: 0.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIOD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.6  Med: 1.87 Max: 7.14
Current: 0.95
0.6
7.14
Price/Tangible Book 0.95
BIOD's Price/Tangible Book is ranked higher than
95% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. BIOD: 0.95 )
Ranked among companies with meaningful Price/Tangible Book only.
BIOD' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.56  Med: 1.8 Max: 6.86
Current: 0.95
0.56
6.86
Earnings Yield (Greenblatt) (%) 360.42
BIOD's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. BIOD: 360.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3953.54  Med: 0 Max: 5045.8
Current: 360.42
-3953.54
5045.8

More Statistics

EPS (TTM) $ -0.19
Beta0.75
Short Percentage of Float0.15%
52-Week Range $0.22 - 0.78
Shares Outstanding (Mil)64.15

Analyst Estimate

Sep16 Sep17 Sep18
Revenue (Mil $)
EPS ($) -0.47 -0.79 -0.84
EPS w/o NRI ($) -0.47 -0.79 -0.84
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for BIOD

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
BIODEL INC Financials Aug 19 2016
BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 12 2016
BIODEL INC Files SEC form 10-Q, Quarterly Report Aug 11 2016
Biodel Reports Third Quarter Fiscal Year 2016 Financial Results Aug 11 2016
BIODEL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Jul 13 2016
Research Report Initiated on Select Drug Manufacturers Equities Jun 27 2016
Biodel Reports Second Quarter Fiscal Year 2016 Financial Results May 31 2016
The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie May 26 2016
BIODEL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... May 26 2016
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well May 25 2016
BIODEL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 25 2016
Biodel/Albireo Limited to Combine; Focus on Liver Diseases May 25 2016
Biodel Inc. and Albireo Limited Agree to Combine May 24 2016
BIODEL INC Files SEC form 10-Q, Quarterly Report May 10 2016
BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 09 2016
Biodel Reports Second Quarter Fiscal Year 2016 Financial Results May 09 2016
BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Apr 01 2016
BIODEL INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or... Mar 24 2016
BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 02 2016
BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)